Viewing data from:

TRI-LO-ESTARYLLA

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A091232 | XIROMED PHARMA ESPANA SL

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Tri-Lo-Estarylla (2023)

Total Spending

$55K

Total Claims

1,812

Beneficiaries

542

Avg Cost/Unit

$0.66

Spending Trend

$34K(2019)→$52K(2020)→$64K(2021)→$60K(2022)→$55K(2023)

YoY Change:+14.9%

5yr CAGR:-4.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Jun 29, 2015

No patent or exclusivity listings for this strength.